ANXA1 and COVID-19: Remarkably, glucocorticoids, which are effective at treating COVID-19 patients, act at least in part via upregulating Annexin I [43], suggesting that natural moderate symptoms for COVID-19 may be linked to effective endogenous immune management, or that patients that respond to glucocorticoid drugs elevate Annexin cell communication pathways that then limit further inflammation, and this response is detectable in our single-cell analysis.